Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures

Beatrice L Brown; Aaron S Kesselheim; Ameet Sarpatwari

doi:10.1371/journal.pmed.1004190

Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures

PLoS Med. 2023 Mar 6;20(3):e1004190. doi: 10.1371/journal.pmed.1004190. eCollection 2023 Mar.

Authors

Beatrice L Brown¹, Aaron S Kesselheim¹, Ameet Sarpatwari¹

Affiliation

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

Abstract

In an analysis of risk evaluation and mitigation strategies for teratogenic drugs, Ameet Sarpatwari, Beatrice Brown and Aaron Kesselheim explore the variation in primary and secondary prevention measures.

Copyright: © 2023 Brown et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Risk Evaluation and Mitigation*
Secondary Prevention
Teratogens* / toxicity

Substances

Teratogens

Grants and funding

ASK and AS's work is supported by Arnold Ventures. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.